Inven Pharmaceuticals Private Limited, a active private limited company, was established on 24 December 1984 in Indore., Madhya Pradesh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232MP1984PTC002701. Registered under ROC Roc Gwalior. it is unlisted. It has an authorized capital of ₹4.50 M and a paid-up capital of ₹3.20 M.
It upholds a compliant status. Employing 85 professional, Its leadership includes Urvashi Patni (Managing Director), Manju Patni (Whole-Time Director), Sohil Patni (Whole-Time Director). Past directors included Lalchand Patni, Urvashi Patni, Sohil Patni. It holds ₹9.02 Cr open charges and ₹1.60 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 27/1, Patel Nagar Main Road,, Indore., Madhya Pradesh, 452001.
U24232MP1984PTC002701
002701
24 December 1984
₹4.50 M
₹3.20 M
Roc Gwalior
Unlisted
Active
Explore comprehensive insights into Inven Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Urvashi Patni | Managing Director | 05 Nov 2024 | Current |
| Manju Patni | Whole-Time Director | 17 Jun 2006 | Current |
| Sohil Patni | Whole-Time Director | 05 Nov 2014 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 24 Jul 2018 | Past |
| Pramod Abcsdd | Whole-Time Director | 29 Sep 2016 | Past |
| Pramod Abcsdd | Whole-Time Director | 01 Jun 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Inven Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.36% increase. The company also saw a substantial improvement in profitability, with a 181.47% increase in profit. The company's net worth moved up by a moderate rise of 1.21%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Inven Pharmaceuticals had a promoter holding of 99.22% and a public holding of 0.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹90,192,000.00
₹16,035,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Dec 2009 | Hdfc Bank Limited | ₹9.00 Cr | Open |
| 29 Oct 1990 | State Bank Of Indore | ₹0.19 M | Open |
| 17 Jan 1995 | State Bank Of Indore | ₹1.00 M | Satisfied |
| 17 Jan 1995 | State Bank Of Indore | ₹1.50 M | Satisfied |
| 29 Mar 1994 | Madhya Pradesh Finance Corporation | ₹1.40 M | Satisfied |
Explore comprehensive loan charge details -
Inven Pharmaceuticals has a workforce of 85 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Inven Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inven Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Inven Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
Progress on Inven Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior. was documented.
The activity Urvashi Patni was appointed as a Managing Director was appointed as a Managing Director on 05 Nov 2024 & has been associated with this company since 1 year 1 month . was completed.
A charge with Hdfc Bank Limited of Rs. 90.00 M registered on 10 Dec 2009 with Charge ID 10193794 was modified on 26 Oct 2018. was recorded as a recent event.
A charge registered on 29 Mar 1994 via Charge ID 90207454 with Madhya Pradesh Finance Corporation was fully satisfied on 07 Mar 2017. was recorded as a recent event.
The activity A charge registered on 29 Mar 1994 via Charge ID 90204943 with Madhya Pradesh Finance Corporation was fully satisfied on 07 Mar 2017. was completed.
The CIN of Inven Pharmaceuticals Private Limited is U24232MP1984PTC002701.
Inven Pharmaceuticals Private Limited is headquartered at 27/1, Patel Nagar Main Road,, Indore., Madhya Pradesh, 452001.
Inven Pharmaceuticals Private Limited was incorporated on 24 December 1984.
The current directors of Inven Pharmaceuticals Private Limited are
The primary industry of Inven Pharmaceuticals Private Limited is Manufacturing.
Inven Pharmaceuticals Private Limited is unlisted.
The authorized capital of Inven Pharmaceuticals Private Limited is ₹4.50 M, and the paid-up capital is ₹3.20 M.
The compliance status of Inven Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX